Regorafenib Plus for third-line treatment in metastatic colorectal cancer: A real-world study

被引：0
|
作者：
Yisilamu, Patiguli [1 ]
Yao, Jiannan [1 ]
Ge, Yang [1 ]
机构：
[1] Capital Med Univ, Beijing Chaoyang Hosp, Dept Oncol, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15562
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study
    Signorelli, Carlo
    Calegari, Maria Alessandra
    Basso, Michele
    Anghelone, Annunziato
    Lucchetti, Jessica
    Minelli, Alessandro
    Angotti, Lorenzo
    Zurlo, Ina Valeria
    Schirripa, Marta
    Chilelli, Mario Giovanni
    Morelli, Cristina
    Dell'Aquila, Emanuela
    Cosimati, Antonella
    Gemma, Donatello
    Ribelli, Marta
    Emiliani, Alessandra
    Corsi, Domenico Cristiano
    Arrivi, Giulia
    Mazzuca, Federica
    Zoratto, Federica
    Morandi, Maria Grazia
    Santamaria, Fiorenza
    Saltarelli, Rosa
    Ruggeri, Enzo Maria
    [J]. CURRENT ONCOLOGY, 2023, 30 (06) : 5456 - 5469
  • [2] Third-line treatment patterns and clinical outcomes for metastatic colorectal cancer: a retrospective real-world study
    Deng, Ting
    Duan, Jingjing
    Bai, Ming
    Zhang, Le
    Li, Hongli
    Liu, Rui
    Ning, Tao
    Ge, Shaohua
    Wang, Xia
    Yang, Yuchong
    Ji, Zhi
    Wang, Feixue
    Ba, Yi
    [J]. THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2023, 14
  • [3] Real-World Data on Sequencing Third-Line Therapies for Metastatic Colorectal Cancer
    Bekaii-Saab, Tanios S.
    David, F.
    Grohne, T.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (05)
  • [4] Regorafenib in the third-line treatment of metastatic colorectal cancer: a retrospective study of 27 cases
    Boudinar, F.
    Larbaoui, B.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [5] Third-line treatment options in metastatic pancreatic cancer patients: a real-world study
    Lu, Hong-Rui
    Zhu, Peng-Fei
    Deng, Ya-Ya
    Chen, Zhe-Ling
    Yang, Liu
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [6] Regorafenib plus tislelizumab for patients with metastatic colorectal cancer: A real-world study
    Gao, Xiang
    Chen, Xiaoping
    Zhao, Yutian
    Mao, Yong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study
    Nie, Caiyun
    Lv, Huifang
    Chen, Beibei
    Xu, Weifeng
    Wang, Jianzheng
    Liu, Yingjun
    Wang, Saiqi
    Zhao, Jing
    He, Yunduan
    Chen, Xiaobing
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [8] BUDGET IMPACT ANALYSIS OF REGORAFENIB IN THE THIRD-LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER
    Zhu, S.
    Liu, J.
    Sun, W.
    Xuan, J.
    [J]. VALUE IN HEALTH, 2018, 21 : S12 - S12
  • [9] Capecitabine plus temozolomide (CapTem): An alternative regimen to regorafenib as third-line setting in metastatic colorectal cancer?
    Ergun, Yakup
    Bal, Oznur
    Dogan, Mutlu
    Uncu, Dogan
    [J]. JOURNAL OF BUON, 2019, 24 (06): : 2435 - 2441
  • [10] Fruquintinib in combination with sintilimab or TAS-102 as third-line or above treatment in patients with metastatic colorectal cancer: a real-world study
    Li, Luchun
    Wang, Ting
    Wu, Zhijuan
    Li, Yan
    Ma, Huiwen
    Wang, Lulu
    Lei, Shuangyi
    Chen, Wen
    [J]. TRANSLATIONAL CANCER RESEARCH, 2023, 12 (11) : 3034 - 3044
12345